Artesunate- amodiaquine

Artesunate- amodiaquine

Access
-
Approved
ASAQ Winthrop®
Sanofi
3-day cure, artemisinin-based combination therapies (TPP-1)
Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5 kg

Dosing
  • Once-daily for 3 days

Efficacy
  • 28-day PCR-corrected ACPR* 94.4%–98.9%

Key features
  • Lower price compared to other prequalified artemisinin-based combination therapies (public-sector tenders)
  • 3-year shelf life
Challenges
  • Amodiaquine resistance in some countries

  • Being withdrawn from countries where SPAQ is deployed for seasonal malaria chemoprevention (SMC) following WHO recommendation

Status
  • 540 million treatments distributed since 2007

  • Approved in 33 countries

Previously
  • DNDi, Sanofi and partners completed development and registration
  • Incorporated into MMV portfolio via collaboration supporting phase IV safety study in Côte d’Ivoire in 2010
Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response